Sanofi chooses Swansea as UKs pioneer Diabetes Centre of Excellence
Category: #health  By Dhananjay Punekar  Date: 2018-05-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi chooses Swansea as UKs pioneer Diabetes Centre of Excellence

Sanofi S.A., a French pharma company, has joined hands with the UK-based Swansea University Medical School, opting for the organization to be the country’s first Diabetes Centre of Excellence. Sanofi has chosen the JCRF (Joint Clinical Research Facility) of the Medical school along with Cymru, Swansea’s diabetes research establishment.

Reportedly, UK’s reputed medical school had already worked with the pharma giant on several critical projects. However, it has been chosen by Sanofi after JCRF repeatedly exhibited its capability to provide excellent services to its customers. For the record, JCRF is the combined entity of Swansea University Medical School & Abertawe Bro Morgannwg University Health Board.

Prof. Steve Bain, the Clinical Lead for the Diabetes Research Unit at Cymru, has stated that the university is looking forward to working on the drug product portfolio in collaboration with Sanofi S.A. Professor Keith Lloyd, the Dean of Swansea, has also reportedly emphasized that the high-quality R&D activities carried out in the field of diabetes at Swansea University will help in tackling the current healthcare issues related to diabetes.

As per Victoria DiBiaso, Global Head of Clinical Operations Strategy & Collaboration at Sanofi, the goal of the collaboration of Sanofi & Swansea is aimed at utilizing JCRF’s knowledge related to diabetes research in clinical tests conducted by Sanofi. She further added that establishing liaisons with reputed research organizations working on diabetes will assist the firm in carrying out medical trials effectively. Experts familiar with the matter claim that the collaboration may prove to be highly beneficial for diabetic patients in the near future.

Sanofi joint venture with the based Swansea University Medical School is speculated to address the social & healthcare requirements of diabetics and explore key areas in diabetes research. Analysts have projected that the partnership will help in fulfilling the unmet medical requirements of patients in addition to supporting the economic growth in Wales.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...